Last $0.93 USD
Change Today 0.00 / 0.00%
Volume 0.0
BMRA On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

biomerica inc (BMRA) Snapshot

Open
$0.93
Previous Close
$0.93
Day High
$0.93
Day Low
$0.93
52 Week High
06/16/14 - $1.10
52 Week Low
03/18/14 - $0.70
Market Cap
7.0M
Average Volume 10 Days
578.8
EPS TTM
$-0.04
Shares Outstanding
7.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOMERICA INC (BMRA)

Related News

No related news articles were found.

biomerica inc (BMRA) Related Businessweek News

No Related Businessweek News Found

biomerica inc (BMRA) Details

Biomerica, Inc. develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which may exist in the human body in extremely small concentrations. Its diagnostic products primarily include diabetes, gastrointestinal, food intolerances, and esoteric tests. The company provides its products primarily to distributors, hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

34 Employees
Last Reported Date: 08/29/14
Founded in 1971

biomerica inc (BMRA) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $141.6K
Chief Financial Officer, Treasurer, Secretary...
Total Annual Compensation: $105.4K
President of Diagnostics Division
Total Annual Compensation: $141.6K
Compensation as of Fiscal Year 2014.

biomerica inc (BMRA) Key Developments

Biomerica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2014

Biomerica Inc. reported earnings results for the second quarter and six months ended November 30, 2014. The company reported net sales of $1,133,600 for the three months ended November 30, 2014, compared to $934,841 for the same period in the previous year, an increase of 21.3%. Net loss for the three months ended November 30, 2014 was $238,028, or $0.03 per share, versus a net loss of $243,357, or $0.03 per share, in the previous fiscal year during the same quarter. Net sales were $2,168,050 for the first six months of fiscal 2015 compared to $1,948,580 for the first six months in fiscal 2014, an increase of 11.3%. The net loss for the six months ended November 30, 2014 was $457,296, or $0.06 per share, compared to net loss of $411,072, or $0.06 per share, in the same period the previous fiscal year.

Biomerica, Inc. Announces Earnings Results for the First Fiscal Quarter Ended August 31, 2014

Biomerica Inc. announced earnings results for the first fiscal quarter ended August 31, 2014. For the quarter, net sales were $1,034,450 compared to $1,013,739 for the same period in the previous year. Net loss was $219,268 compared to $167,714 in fiscal 2014. The increase in the loss was primarily due to the increase in research and development spending, a majority of which was invested in the company's new Gastroenterology test and exploring the possibility of obtaining FDA clearance. Research and Development spending was $195,706 compared to $91,257 the previous quarter, an increase of $104,449. Net cash flow provided from operations was $143,641 compared to net cash used in operation of $376,271 in the same quarter the previous fiscal year, an increase of $519,912.

Biomerica Inc., Annual General Meeting, Dec 15, 2014

Biomerica Inc., Annual General Meeting, Dec 15, 2014., at 10:00 Pacific Standard Time. Location: 17571 Von Karman Avenue. Agenda: To consider the election of five directors, each to serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal; to consider and act upon a proposal to ratify and approve the company's 2014 stock incentive plan; and to ratify the selection by the audit committee of the company's Board of Directors of PKF, Certified Public Accountants for the current fiscal year; and to consider transaction of such other business which may properly come before the annual meeting and any adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRA:US $0.93 USD 0.00

BMRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IDEXX Laboratories Inc $158.42 USD -4.90
Neogen Corp $46.10 USD -2.07
OraSure Technologies Inc $9.19 USD -0.58
Trinity Biotech PLC $18.54 USD -0.25
View Industry Companies
 

Industry Analysis

BMRA

Industry Average

Valuation BMRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERICA INC, please visit www.biomerica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.